AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Files Resale Registration Statement for Convertible Senior Notes SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that it has filed a Form S-3 resale registration statement with the Securities and Exchange Commission. The registration statement was in connection with its recent private placement of $200 million aggregate principal amount of 2.5% convertible senior notes due 2011. Upon being declared effective by the Securities and Exchange Commission, the registration statement will allow selling securityholders to publicly resell the convertible notes and the common stock issuable upon their conversion, subject to the prospectus delivery requirements of the Securities Act of 1933, as amended. A written prospectus, when available, may be obtained from Amylin at 9360 Towne Centre Drive, Suite 110, San Diego, California 92121, Attention: General Counsel. The resale registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, the resale registration statement must be declared effective by the Securities and Exchange Commission before it may be used by selling securityholders for resales of their securities. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200

Copyright